Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Diabetes Metab J. 2022 Sep;46(5):722-732. doi: 10.4093/dmj.2021.0225. Epub 2022 Mar 8.
We assessed the myocardial infarction (MI), stroke, and all-cause death risks during follow-up according to the low-density lipoprotein cholesterol (LDL-C) levels among older adults.
The Korean National Health Insurance Service datasets (2002 to 2020) were used for this population-based cohort study. The hazards of MI, stroke, and all-cause mortality during follow-up were analyzed according to LDL-C level in individuals aged ≥65 years without baseline cardiovascular diseases (n=1,391,616).
During a mean 7.55 years, 52,753 MIs developed; 84,224 strokes occurred over a mean 7.47 years. After a mean 8.50 years, 233,963 died. A decrease in LDL-C was associated with lower hazards of MI and stroke. The decreased hazard of stroke in lower LDL-C was more pronounced in statin users, and individuals with diabetes or obesity. The hazard of all-cause death during follow-up showed an inverted J-shaped pattern according to the LDL-C levels. However, the paradoxically increased hazard of mortality during follow-up in lower LDL-C was attenuated in statin users and individuals with diabetes, hypertension, or obesity. In statin users, lower LDL-C was associated with a decreased hazard of mortality during follow-up.
Among the elderly, lower LDL-C was associated with decreased risks of MI and stroke. Lower LDL-C achieved by statins in the elderly was associated with a decreased risk of all-cause death during follow-up, suggesting that LDL-C paradox for the premature death risk in the elderly should not be applied to statin users. Intensive statin therapy should not be hesitated for older adults with cardiovascular risk factors including diabetes.
我们评估了老年人的低密度脂蛋白胆固醇(LDL-C)水平与随访期间心肌梗死(MI)、中风和全因死亡风险之间的关系。
本基于人群的队列研究使用了韩国国家健康保险服务数据集(2002 年至 2020 年)。对无基线心血管疾病(n=1,391,616)的≥65 岁个体,根据 LDL-C 水平分析了随访期间 MI、中风和全因死亡的风险。
在平均 7.55 年期间,发生了 52,753 例 MI;在平均 7.47 年期间发生了 84,224 例中风。经过平均 8.50 年,有 233,963 人死亡。LDL-C 降低与 MI 和中风风险降低相关。较低 LDL-C 水平下中风风险的降低在他汀类药物使用者和患有糖尿病或肥胖症的个体中更为明显。随访期间全因死亡的风险呈倒 J 形模式。然而,在他汀类药物使用者和患有糖尿病、高血压或肥胖症的个体中,随访期间 LDL-C 降低与死亡率增加的悖论关系减弱。在他汀类药物使用者中,较低的 LDL-C 与随访期间死亡率降低相关。
在老年人中,较低的 LDL-C 与 MI 和中风风险降低相关。老年人使用他汀类药物降低 LDL-C 与随访期间全因死亡风险降低相关,这表明 LDL-C 悖论不应用于老年人群的过早死亡风险,对于有心血管危险因素(包括糖尿病)的老年人,应积极进行强化他汀类药物治疗。